Thermo Fisher Scientific has just reported Q1 2026 results, and the market's positioning has shifted meaningfully from the defensive crouch seen going in.
The clearest signal is in options. Heading into the print, the put/call ratio was running well above its 20-day average — a consistent theme across recent notes. That has reversed sharply. The PCR has dropped to 1.10, more than 2.6 standard deviations below its 20-day mean of 1.27. That is the most call-heavy reading relative to recent norms in months, and it puts the ratio closer to its 52-week low of 0.51 than its high of 2.27. The defensive hedging that defined options positioning through April and early May has unwound fast.
Short positioning tells a consistent story. SI % FF eased to 1.28% — down slightly on the week and fractionally off the monthly peak of around 1.32% seen earlier in May. The month-on-month build that drove much of the pre-earnings narrative has stalled. Shorts added aggressively through the first two weeks of May, but the pace has halted at the event. Borrow costs remain trivially cheap at 0.30%, down nearly 29% on the week, and availability is effectively unlimited — borrow supply vastly exceeds short demand, leaving no squeeze mechanics in play.
The Street's posture is harder to read after a run of one-way target cuts. Every analyst action since mid-April has been a reduction: Wells Fargo to $615, Stifel to $600, Baird to $639, Barclays to $625. Ratings held — Overweight and Buy ratings remained intact across those moves — but the trajectory was clear. The mean target at $612 now implies roughly 37% upside from the current $447.81 close. The bull case rests on life science solutions segment compounding at a 5.4% CAGR and the Clario acquisition deepening CRO exposure as biopharma outsourcing accelerates. Bears point to the 830-basis-point EBIT margin decline between 2021 and 2024, and a biotech funding backdrop that remained soft heading into the year. At 17.4x trailing PE and 15.5x EV/EBITDA, the multiple is not demanding for a franchise of this quality — but it prices in a recovery that margins have yet to confirm.
The earnings history adds context here. The April 2026 print moved the stock down 8.6% in a day and 6.8% over five days. The prior quarter saw an 11% decline. Two consecutive hard post-earnings drops established a pattern that clearly shaped the defensive options positioning seen going in. The fact that PCR has swung this sharply toward calls in the immediate aftermath suggests either the print was better than feared, or at minimum that the worst-case positioning has been unwound.
Peer performance on the week is worth noting. CRL fell nearly 10% — the sharpest move in the group — while DHR held broadly flat, down less than half a percent on the week. RGEN and BRKR both dropped around 4-5%. TMO's 2.5% weekly decline is middling within a group that broadly struggled, which is a modest improvement relative to recent weeks when it was underperforming the cohort more visibly.
The key question now is whether the post-earnings options shift reflects genuine fundamental relief or simply the removal of event-related hedges. With no confirmed next earnings date yet visible, the focus turns to management commentary on margin trajectory and the pace of the biotech funding recovery — two variables that drove the analyst target-cut cycle and will determine whether the 37% gap to consensus closes from the top down or the bottom up.
See the live data behind this article on ORTEX.
Open TMO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
